Moshe Jakubowski

Moshe Jakubowski

Auto-generated profile, based on publicly available information

Moshe Jakubowski

Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RBRami Burstein
Rami Burstein
BCBeth Collins
Beth Collins
MJMoshe Jakubowski
Moshe Jakubowski

10 January 2010 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RNRodrigo Noseda
Rodrigo Noseda
VKVanessa Kainz
Vanessa Kainz
MJMoshe Jakubowski
Moshe Jakubowski
JGJoshua J Gooley
Joshua J Gooley
CSClifford B Saper
Clifford B Saper
RBRami Burstein
Rami Burstein
Light makes migraines worse. The authors show that this effect can be mediated by intrinsically photosensitive retinal ganglion cells projecting onto thalamic neurons that also receive nociceptive input from the dura mater. The perception of migraine headache, which is mediated by nociceptive signals transmitted from the cranial dura mater to the brain, is uniquely exacerbated by exposure to light. We found that exacerbation of migraine headache by light is prevalent among blind individuals who maintain non–image-forming photoregulation in the face of massive rod/cone degeneration. Using single-unit recording and neural tract tracing in the rat, we identified dura-sensitive neurons in the posterior thalamus whose activity was distinctly modulated by light and whose axons projected extensively across layers I–V of somatosensory, visual and associative cortices. The cell bodies and dendrites of such dura/light-sensitive neurons were apposed by axons originating from retinal ganglion cells (RGCs), predominantly from intrinsically photosensitive RGCs, the principle conduit of non–image-forming photoregulation. We propose that photoregulation of migraine headache is exerted by a non–image-forming retinal pathway that modulates the activity of dura-sensitive thalamocortical neurons.

30 June 2010 in The Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
XZXiChun Zhang
XiChun Zhang
DLDan Levy
Dan Levy
RNRodrigo Noseda
Rodrigo Noseda
VKVanessa Kainz
Vanessa Kainz
MJMoshe Jakubowski
Moshe Jakubowski
RBRami Burstein
Rami Burstein
Attacks of migraine with aura represent a phenomenon in which abnormal neuronal activity in the cortex produces sensory disturbances (aura) some 20–40 min before the onset of headache. The purpose of this study was to determine whether cortical spreading depression (CSD)—an event believed to underlie visual aura—can give rise to activation of nociceptors that innervate the meninges—an event believed to set off migraine headache. CSD was induced in anesthetized male rats by stimulation of the visual cortex with electrical pulses, pin prick, or KCl; single-unit activity of meningeal nociceptors was monitored in vivo in the rat before and after CSD. Regardless of the method of cortical stimulation, induction of CSD was recorded in 64 trials. In 31 of those trials, CSD induced a twofold increase in meningeal nociceptor firing rate that persisted for 37.0 ± 4.6 min in trials in which activity returned to baseline, or >68 min in trials in which activity remained heightened at the time recording was interrupted. In two-thirds of the trials, onset of long-lasting neuronal activation began ∼14 min after the wave of CSD. The findings demonstrates for the first time that induction of CSD by focal stimulation of the rat visual cortex can lead to long-lasting activation of nociceptors that innervate the meninges. We suggest that migraine with aura is initiated by waves of CSD that lead up to delayed activation of the trigeminovascular pathway.

29 April 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RBRami Burstein
Rami Burstein
MJMoshe Jakubowski
Moshe Jakubowski
EGEsther Garcia‐Nicas
Esther Garcia‐Nicas
VKVanessa Kainz
Vanessa Kainz
ZBZahid Bajwa
Zahid Bajwa
DBDavid Borsook
David Borsook

17 November 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
XZXiChun Zhang
XiChun Zhang
DLDan Levy
Dan Levy
VKVanessa Kainz
Vanessa Kainz
RNRodrigo Noseda
Rodrigo Noseda
MJMoshe Jakubowski
Moshe Jakubowski
RBRami Burstein
Rami Burstein

8 January 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SKSlavenka Kam-Hansen
Slavenka Kam-Hansen
MJMoshe Jakubowski
Moshe Jakubowski
JKJohn M. Kelley
John M. Kelley
IKIrving Kirsch
Irving Kirsch
DHDavid C. Hoaglin
David C. Hoaglin
RBRami Burstein
Rami Burstein
Information provided to patients is thought to influence placebo and drug effects. In a prospective, within-subjects, repeated-measures study of 66 subjects with episodic migraine, we investigated how variations in medication labeling modified placebo and drug effects. An initial attack with no treatment served as a control. In six subsequent migraine attacks, each participant received either placebo or Maxalt (10-mg rizatriptan) administered under three information conditions ranging from negative to neutral to positive (told placebo, told Maxalt or placebo, told Maxalt) (N = 459 documented attacks). Treatment order was randomized. Maxalt was superior to placebo for pain relief. When participants were given placebo labeled as (i) placebo, (ii) Maxalt or placebo, and (iii) Maxalt, the placebo effect increased progressively. Maxalt had a similar progressive boost when labeled with these three labels. The efficacies of Maxalt labeled as placebo and placebo labeled as Maxalt were similar. The efficacy of open-label placebo was superior to that of no treatment. Relative to no treatment, the placebo, under each information condition, accounted for more than 50% of the drug effect. Increasing “positive” information incrementally boosted the efficacy of both placebo and medication during migraine attacks. The benefits of placebo persisted even if placebo was honestly described. Whether treatment involves medication or placebo, the information provided to patients and the ritual of pill taking are important components of care.